Covington & Burling advised Alexion on the transaction while Arnold & Porter represented Pfizer. AstraZeneca Rare Disease announced its entry into a definitive purchase and license agreement...
Alexion, AstraZeneca Rare Disease in Deal with Pfizer
Humacyte’s $160 Million Funding Arrangement
Covington advised Humacyte on the deal. Humacyte, Inc. announced its $150 million revenue-based funding arrangement, as well as a $10 million equity investment option, with Oberland...